References
[1] Bhimraj, A., et al., Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19[J], Clin Infect Dis, 2020.
[2] Chen, Z.R., et al., Pharmacotherapics Advice in Guidelines for COVID-19[J], Front Pharmacol, 2020. 11 : p. 950.
[3] Singh, A., et al., Efficacy and safety of tocilizumab in treatment of Takayasu arteritis: A systematic review of randomized controlled trials[J], Mod Rheumatol, 2021. 31 (1): p. 197-204.
[4] Castañeda, S., et al., Tocilizumab for the treatment of adult-onset Still’s disease[J], Expert Opin Biol Ther, 2019.19 (4): p. 273-286.
[5] Hellmich, B., et al., 2018 Update of the EULAR recommendations for the management of large vessel vasculitis[J],Ann Rheum Dis, 2020. 79 (1): p. 19-30.
[6] Tunnicliffe, D.J., et al., Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines[J], Arthritis Care Res (Hoboken), 2015. 67 (10): p. 1440-52.
[7] Fanouriakis, A., et al., 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J], Ann Rheum Dis, 2019. 78 (6): p. 736-745.
[8] Gordon, C., et al., The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults[J], Rheumatology (Oxford), 2018. 57 (1): p. e1-e45.
[9] Yates, M., et al., EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis[J], Ann Rheum Dis, 2016.75 (9): p. 1583-94.
[10] Ntatsaki, E., et al., BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis[J],Rheumatology (Oxford), 2014. 53 (12): p. 2306-9.
[11] Hatemi, G., et al., 2018 update of the EULAR recommendations for the management of Behçet’s syndrome[J], Ann Rheum Dis, 2018. 77 (6): p. 808-818.
[12] Kone-Paut, I., et al., French recommendations for the management of Behçet’s disease[J], Orphanet J Rare Dis, 2021.16 (Suppl 1): p. 352.
[13] Ramos-Casals, M., et al., EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies[J], Ann Rheum Dis, 2020. 79 (1): p. 3-18.
[14] Price, E.J., et al., The British Society for Rheumatology guideline for the management of adults with primary Sjögren’s Syndrome[J], Rheumatology (Oxford), 2017. 56 (10): p. 1828.
[15] Bellutti Enders, F., et al., Consensus-based recommendations for the management of juvenile dermatomyositis[J],Ann Rheum Dis, 2017. 76 (2): p. 329-340.
[16] Kobayashi, I., et al., Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update[J], Mod Rheumatol, 2020.30 (3): p. 411-423.
[17] Ughi, N., et al., The Italian Society of Rheumatology clinical practice guidelines for the management of polymyalgia rheumatica[J], Reumatismo, 2020. 72 (1): p. 1-15.
[18] Dasgupta, B., et al., BSR and BHPR guidelines for the management of polymyalgia rheumatica[J], Rheumatology (Oxford), 2010. 49 (1): p. 186-90.
[19] Hamilton, L., et al., BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics[J], Rheumatology (Oxford), 2017. 56 (2): p. 313-316.
[20] Gossec, L., et al., EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update[J], Ann Rheum Dis, 2020. 79 (6): p. 700-712.
[21] Coates, L.C., et al., The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics[J],Rheumatology (Oxford), 2013. 52 (10): p. 1754-7.
[22] Akiyama, M., Y. Kaneko, and T. Takeuchi, Effectiveness of tocilizumab in Behcet’s disease: A systematic literature review[J],Semin Arthritis Rheum, 2020. 50 (4): p. 797-804.
[23] Akiyama, M., Y. Kaneko, and T. Takeuchi, Tocilizumab in isolated polymyalgia rheumatica: A systematic literature review[J],Semin Arthritis Rheum, 2020. 50 (3): p. 521-525.
[24] Chen, C., et al., Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-Analysis[J], Medicine (Baltimore), 2016.95 (11): p. e3060.
[25] Kaneko, Y., et al., Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial[J],Ann Rheum Dis, 2018. 77 (12): p. 1720-1729.
[26] Felten, R., et al., Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial[J], Ann Rheum Dis, 2020.
[27] Khanna, D., et al., Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial[J],Lancet Respir Med, 2020. 8 (10): p. 963-974.
[28] Zhang, C., et al., Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial[J], Lancet Neurol, 2020. 19 (5): p. 391-401.
[29] Nakaoka, Y., et al., Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study[J], Rheumatology (Oxford), 2020. 59 (9): p. 2427-2434.
[30] Illei, G.G., et al., Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study[J], Arthritis Rheum, 2010. 62 (2): p. 542-52.
[31] Moulis, G., et al., Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study[J],Ann Rheum Dis, 2018. 77 (8): p. 1172-1178.
[32] Kondo, M., et al., A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis?[J], Rheumatology (Oxford), 2014.53 (10): p. 1907-8.
[33] Madureira, P., et al., Off-label Use of Tocilizumab in Psoriatic Arthritis: Case Series and Review of the Literature[J],Acta Reumatol Port, 2016. 41 (3): p. 251-255.
[34] Sakai, R., et al., Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review[J], Clin Rheumatol, 2017. 36 (10): p. 2383-2392.
[35] Carroll, M.B., Tocilizumab in the treatment of myocardial infarction[J], Mod Rheumatol, 2018. 28 (5): p. 733-735.
[36] Alzghari, S.K. and V.S. Acuña, Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review[J], J Clin Virol, 2020. 127 : p. 104380.